

## Investment focus

The fund's aim is to achieve capital growth in the long term. The BB Adamant Sustainable Healthcare Fund invests in healthcare firms with strong sustainability credentials and innovative business models. Examples of sustainability in the healthcare industry are environmentally sound procurement policies for drug makers, high safety standards for medical products and services, and a commitment to ethics when conducting clinical trials. From the perspective of the patient, the early diagnosis of life-threatening diseases, personalized medicine enabling highly selective treatments and efficient treatment procedures are key sustainability indicators. A variety of high-growth themes, smart stock selection using our established investment process and the application of sustainability criteria are the fund's tools for achieving attractive returns. The Fund takes ESG factors into consideration while implementing the aforementioned investment objectives.

## Fund facts

NAV	197.53
Volume	EUR 243.5 mn
NAV-calculation	Daily "Forward Pricing"
Cut off time	15:00 CET
Distribution policy	Accumulating
Investment manager	Bellevue Asset Management AG
Custodian	RBC Investor Services, Luxembourg
Launch date	29.06.2018
Fiscal year end	30.06.
Benchmark	MSCI World Health Care Net

ISIN code	LU1819586006
Valor	41670705
Bloomberg	BBSHCIE LX
WKN	A2JMRK

Management fee	0.90%
Performance fee	none
Subscription fee	up to 5%
Min. investment	n.a.


Legal entity	Luxembourg UCITS V SICAV
Countries of distribution	AT, CH, DE, ES, LU, UK, IT (Inst.)
EU SFDR 2019/2088	Article 8

## Key figures

Beta	n.a.
Correlation	n.a.
Volatility	n.a.
Tracking Error	n.a.
Active Share	n.a.
Sharpe Ratio	n.a.
Information Ratio	n.a.
Jensen's Alpha	n.a.

Source: Bellevue Asset Management, 31.08.2021;  
Calculation over 3 years.

## Indexed performance since launch




## Cumulated & annualized performance

	Cumulated						Annualized			
	1 month	YTD	1 year	3 years	5 years	since launch	1 year	3 years	5 years	since launch
I EUR	0.4%	16.8%	24.4%	46.0%	n.a.	58.0%	24.4%	13.4%	n.a.	15.5%
BM	3.2%	21.3%	24.9%	48.8%	n.a.	63.7%	24.9%	14.1%	n.a.	16.8%

## Annual performance

	2016	2017	2018	2019	2020	YTD
I EUR	n.a.	n.a.	n.a.	26.8%	18.6%	16.8%
BM	n.a.	n.a.	n.a.	25.7%	4.3%	21.3%

## Rolling 12-month-performance



Source: Bellevue Asset Management, 31.08.2021; all figures in EUR %, total return / BVI-methodology

Past performance is not a reliable indicator of future results and can be misleading. As the subfund is denominated in a currency that may differ than an investor's base currency, changes in the rate of exchange may have an adverse effect on prices and incomes. Performance is shown net of fees and expenses for the relevant share class over the reference period. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. Individual costs are not taken into account and would have a negative impact on the performance. With an investment amount of EUR 1,000 over an investment period of five years, the investment result in the first year would be reduced by the front-end load of up to EUR 50 (5%) as well as by additional individual custody charges. In subsequent years, the investment result would also be reduced by the individual custody account costs incurred. The reference benchmark of this class is used for performance comparison purposes only (dividend reinvested). No benchmark is directly identical to a subfund, thus the performance of a benchmark is not a reliable indicator of future performance of the subfund it is compared to. There can be no assurance that a return will be achieved or that a substantial loss of capital will not be incurred.

## Top 10 positions

Regeneron Pharma.		4.3%
Iqvia		4.1%
HCA Holdings		3.9%
Intuitive Surgical		3.7%
Laboratory Corp		3.5%
Novo Nordisk		3.2%
Sartorius Stedim Biotech		3.2%
Lonza		3.1%
Centene		3.1%
Sonova Holding AG		3.1%
Total top 10 positions		35.2%
Total positions		40

## Sector breakdown

Services		31.3%
Biotechnology		24.8%
Medtech		19.6%
Generics		13.3%
Pharma		9.4%
Cash		1.6%

## Geographic breakdown

United States		34.3%
China		16.2%
Switzerland		11.7%
Denmark		11.3%
Japan		8.1%
Australia		4.7%
France		3.2%
Great Britain		2.5%
Jordan		2.5%
South Korea		2.4%
New Zealand		1.4%
Cash		1.7%

## Market commentary

August was another friendly month for stock markets around the world and showed a positive return. Market advances in August were largely fueled by reports of robust quarterly results. The rapid global spread of the delta variant triggered a temporary risk-off move by investors, though, and surprising signs of a cooling US economy, which can be largely blamed on supply chain constraints, blew some froth off international stock markets. Federal Reserve officials didn't make any comments at the virtual central bank gathering in Jackson Hole that swayed the markets this year. The US central bank did push its plans for scaling back its expansionary monetary policy by tapering its asset purchases further into the future though. At the same time, it kept its key lending rate unchanged. The Fed based its decision on forecasting uncertainty related to the course of the pandemic and to the ensuing social and economic effects. Against this background the broad MSCI World index rose 2.5% in USD. The MSCI World Healthcare Index performed slightly better, gaining 2.8% over the month. The BB Adamant Sustainable Healthcare Fund was unable to keep up with the stock market bulls and closed the month with a flat performance (USD / I shares).

The following positions made positive contributions to the portfolio's monthly performance: Regeneron, the US biotech company, made strong gains after reporting very solid quarterly results. Another trigger for the sharp upward move in Regeneron shares was the strong demand for its antibody cocktail which helps prevent and treat COVID-19, developed in collaboration with Roche. Shares of vaccine specialist Bavarian Nordic were also marked up sharply in August. Its re-rating was triggered by the announcement that the Danish Ministry of Health was providing DKK 800 mn to help fund a Phase III trial of ABNCoV2, Bavarian Nordic's COVID-19 booster vaccine candidate. Healthcare companies listed in Hong Kong, which are overweighted in the fund, led the list of declining stocks and this also explains the fund's underperformance during the past month versus its direct benchmark. Chinese government intervention in several domestic industries hit tech stocks the hardest and, after a difficult July, investors continued to show little interest in Chinese stocks in August. Healthcare firms were not directly hit by this turbulence, but they are now trading with an increased "China risk" premium. Meanwhile investors turned to large-cap names in defensive industries and in the healthcare sector, these are the big pharma players, which are underweighted in the fund.

## Investment process

BB Adamant's rule-based investment approach, which has been successfully implemented since 2007 and is also mapped by the Adamant Global Healthcare Index, serves as the basis for the fund. A universe with around 600 stocks is compiled from a global pool with over 4000 listed healthcare stocks based on a preselection. As an additional step compared to the conventional methodology, ESG risks of these 600 investable stocks are identified, which could affect the economic value of a company. Here we rely on the longstanding expertise of our research partner Sustainalytics.

In order to get into the fund portfolio, the companies must meet the following criteria: Appropriate ESG risk profile (best-in-class approach), not involved in severe ESG-relevant controversies and comply with the ten principles of the UN Global Compact. In the case of controversial business areas and practices, revenue thresholds are defined for inclusion. The results of the ESG filter application demonstrate that around 40-50% of the titles meet our strict sustainability requirements. The proven factor analysis is then carried out according to four quantitative and four qualitative parameters. The objective here is to select companies that are inexpensive, have strong growth and have an exceptional competitive position so that they can maintain their leading position also in the future.

The analysis results in a portfolio structure consisting of the 40 most sustainable stocks in the healthcare industry, ten of them per region (Western Europe, North America, Japan / Oceania, emerging markets). The application of the eight factors in the past has typically led to a focus on mid cap stocks and an underweight position in pharma and the North America region relative to the MSCI World Healthcare Index. The rebalancing takes place every six months.

Source: Bellevue Asset Management, 31.08.2021;

For illustrative purposes only. Holdings and allocations are subject to change. Any reference to a specific company or security does not constitute a recommendation to buy, sell, hold or directly invest in the company or securities. Where the subfund is denominated in a currency other than an investor's base currency, changes in the rate of exchange may have an adverse effect on price and income.

## Risk and return profile

The aim of the fund is to achieve a good and competitive level of capital growth over the long term. It is especially suitable for investors who wish to focus on sustainability and have an investment horizon of at least five years. The fund exhibits the level of risk that is typical of equity investments.



This fund is assigned to this category, as its share price fluctuates severely and both the risk of loss and the opportunities for profit can therefore be high. The calculation of the risk and earnings profile is based on simulated/historical data, which cannot be used as a reliable indication of the future risk profile. The classification of the fund may change in future and does not constitute a guarantee. Even a fund classed in category 1 does not constitute a completely risk-free investment. There can be no guarantee that a return will be achieved or that a substantial loss of capital will not be incurred. The overall risk exposure may have a strong impact on any return achieved by the fund or subfund. For further information please refer to the fund prospectus or KIID.

### Liquidity risk

The fund may invest some of its assets in financial instruments that may in certain circumstances reach a relatively low level of liquidity, which can have an impact on the fund's liquidity.

### Risk arising from the user of derivatives

The fund may conclude derivatives transactions. This increases opportunities, but also involves an increased risk of loss.

### Currency risks

The fund may invest in assets denominated in a foreign currency. Changes in the rate of exchange may have an adverse effect on prices and incomes.

### Operational risks and custody risks

The fund is subject to risks due to operational or human errors, which can arise at the investment company, the custodian bank, a custodian or other third parties.

## Target market

The fund is suitable for retail and professional investors in Austria, Germany, Luxembourg, Spain and Switzerland.

## Chances

- Investments in the 40 most attractive healthcare stocks worldwide with due account taken of current sustainability criteria.
- Many years of recognized bottom up expertise coupled with comprehensive sustainability research from Sustainalytics.
- The sustainability filter combines a best-in-class approach with the application of a strict exclusion procedure.
- Proprietary investment process: Half-yearly company evaluation and rebalancing.
- Underweighting of pharma and US stocks against the relevant healthcare indices, and a strong focus on mid caps.

## Inherent risks

- The fund invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- The fund may invest a proportion of its assets in financial instruments that might under certain circumstances have a relatively low level of liquidity, which can in turn affect the fund's liquidity.
- The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- Investing in emerging markets entails the additional risk of political and social instability.
- The fund may engage in derivatives transactions. The increased opportunities gained come with an increased risk of losses.

You can find a detailed presentation of the risks faced by this fund in the "Special Investment Risks" section of the sales prospectus.

## Management Team



**Zahide Donat**  
Portfolio Manager  
since inception of the fund



**Dr. Cyrill Zimmermann**  
Portfolio Manager  
since inception of the fund



**Samuel Stursberg**  
Portfolio Manager  
since inception of the fund

## Awards



## Sustainability Profile – ESG

**Norms-based exclusions:**  Compliance UNGC, HR, ILO  
**ESG Risk Analysis:**  ESG Integration  
**Stewardship:**  Engagement

Controversial weapons  
 Best-in-Class  
 Proxy Voting

**CO2 intensity (t CO2/mn USD sales):** 43.4 t (low)  
**MSCI ESG Rating (AAA - CCC):** A  
**Sustainalytics ESG Risk Rating:** 24.6 (medium)  
**EU SFDR 2019/2088 product category:** Article 8

MSCI ESG coverage: 100%  
MSCI ESG coverage: 100%

Based on portfolio data as per 30.06.2021 (quarterly updates) – ESG data base on MSCI ESG Research and are for information purposes only; compliance with global norms according to the principles of UN Global Compact (UNGC), UN Guiding Principles for Business and Human Rights (HR) and standards of International Labor Organisation (ILO); no involvement in controversial weapons; ESG Integration: Sustainability risks are considered while performing stock research and portfolio construction; Best-in-class: systematic exclusion of "ESG laggards"; MSCI ESG Rating ranges from "leaders" (AAA-AA), "average" (A, BBB, BB) to "laggards" (B, CCC). Sustainalytics' ESG Risk Rating ranges from 0 "negligible" to 100 "severe". Note: in certain cases the ESG rating methodology may lead to a systematic discrimination of companies or industries, the manager may have good reasons to invest in supposed "laggards". The CO2 intensity expresses MSCI ESG Research's estimate of GHG emissions measured in tons of CO2 per USD 1 million sales; for further information c.f. [www.bellevue.ch/en/corporate-information/sustainability](http://www.bellevue.ch/en/corporate-information/sustainability)

## Important information

This marketing communication relates to Bellevue Funds (Lux) (hereinafter the “Fund”), an investment company with variable capital “société à capital variable” (SICAV) under the current version of the Law of the Grand Duchy of Luxembourg of 10 August 1915 on commercial companies (“Law of 1915”) and is authorized under Part I of the Law of 17 December 2010 relating to undertakings for collective investment (“Law of 2010”) as an undertaking for collective investment (UCITS). BB Adamant Sustainable Healthcare is a subfund of Bellevue Funds (Lux).

This marketing communication is issued by Bellevue Asset Management AG, which is an authorized asset manager subject to the supervision of the Swiss Financial Market Supervisory Authority (FINMA) and acts as an Investment Manager of the Fund. The Prospectus, statutes, the annual and half-yearly report, the share prices and further information about the Fund can be obtained free of charge in English and German from the management company of the Fund, Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht, from the representative, paying, facilities and information agents mentioned below or online at [www.bellevue.ch](http://www.bellevue.ch). The Key Investor Information documents are available free of charge in the languages of the countries of distribution at [www.fundinfo.com](http://www.fundinfo.com).

This document is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. It is particularly not intended for US persons, as defined under Regulation S of the U.S. Securities Act of 1933, as amended. The information and data presented in this document are not to be considered as an offer to buy, sell or subscribe to any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient and in particular tax treatment depends on individual circumstances and may be subject to change. This document is not to be relied upon in substitution for the exercise of independent judgment. Before making any investment decision, investors are recommended to ascertain if this investment is suitable for them in the light of their financial knowledge and experience, investment goals and financial situation, or to obtain specific advice from an industry professional. The details and opinions contained in this document are not to be considered as recommendation or investment advice. Every investment involves risk, especially with regard to fluctuations in value and return, and investors’ capital may be at risk. If the currency of a financial product is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. Past performance is no indicator for the current or future performance. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions. Commissions and costs have a negative impact on performance. For more information about the associated costs, please refer to the related costs and fees section of the prospectus. Any benchmarks/indices cited herein are provided for information purposes only. No benchmark/index is directly comparable to the investment objectives, strategy or universe of the subfund. The performance of a benchmark shall not be indicative of past or future performance of the sub-fund. Financial transactions should only be undertaken after having carefully studied the current valid prospectus and are only valid on the basis of the latest version of the prospectus and available annual and half-yearly reports. Please take note of the risk factors.

### Countries of distribution and local representatives

The Bellevue Funds (Lux) is registered and admitted for public distribution in AT, DE, LU, ES, UK, IT (Inst.) and CH.

**Austria:** Paying and information agent: ERSTE BANK der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna

**Germany:** Information agent: ACOLIN Europe GmbH, Reichenaustrasse 11a-c, D-78467 Konstanz

**Spain:** Representative: atl Capital, Calle de Montalbán 9, ES-28014 Madrid - CNMV under the number 938

**Switzerland:** The Bellevue Funds (Lux) SICAV is registered for public offering and distribution in Switzerland with the Swiss Financial Market Supervisory Authority. Representative agent in Switzerland: Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne. Paying agent in Switzerland: DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, P.O. Box, CH-8022 Zürich. You can obtain the sales prospectus, Key Investor Information Document (“KIID”), statutes and the current annual and half-yearly reports, the current share prices and further information about the fund free of charge in German from the management company Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht, the representative agent in Switzerland or online at [www.bellevue.ch](http://www.bellevue.ch). In respect of the units distributed in or from Switzerland, the place of performance and jurisdiction is at the registered office of the representative agent.

Copyright©2021 Bellevue Asset Management, Inc. All rights reserved.

Citywire information is proprietary and confidential to Citywire Financial Publishers Ltd (“Citywire”), may not be copied and Citywire excludes any liability arising out of its use.

© 2021 MSCI ESG Research LLC. Reproduced by permission. Although Bellevue Asset Management information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the “ESG Parties”), obtain information from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness of any data herein. None of the ESG Parties makes any express or implied warranties of any kind, and the ESG Parties hereby expressly disclaim all warranties of merchantability and fitness for a particular purpose, with respect to any data herein. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein. Further, without limiting any of the foregoing, in no event shall any of the ESG Parties have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

The most important terms are explained in the glossary at [www.bellevue.ch/en/glossary](http://www.bellevue.ch/en/glossary)